Skip to main content
TipRanks
Go Ultimate75% OFF

enVVeno Medical (NVNO) Stock Price & Analysis

376 Followers

NVNO Stock Chart & Stats

$5.57-$0.20(-3.47%)
At close: 4:00 PM EST
$6$8$10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$5.43 - $5.85
52-Week Range
$5.43 - $14.69
Previous Close
$5.77
Volume
N/A
Average Volume (3M)
36.12K
Market Cap
$3.87M
Enterprise Value
-$12.65M
Total Cash (Recent Filing)
$18.47M
Total Debt (Recent Filing)
$408.00K
Price to Earnings (P/E)
―
Beta
1.82
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low leverage reduces fixed financial obligations and preserves balance-sheet flexibility while the company advances its device programs. This can provide greater capacity to fund development and absorb setbacks than a similarly loss-making business with substantial debt.

Sustained Clinical Benefit

Three-year clinical improvements support the durability of VenoValve’s therapeutic benefit rather than a short-lived response. Sustained reductions in disease severity and improvements in symptoms and quality of life could strengthen physician adoption and future commercial credibility.

Next-generation Product Pipeline

The FDA-authorized TAVVE study advances enVVe, a less invasive replacement valve designed for light sedation and same-day discharge. If clinical development succeeds, this product could broaden procedural accessibility and extend the company’s opportunity beyond open-surgery VenoValve.

Bears Say

No Commercial Revenue

The absence of reported revenue shows that the company has not yet converted its technology into a commercial business. Until product approval, launch and adoption occur, financial performance remains dependent on clinical progress rather than recurring customer demand or operating scale.

Persistent Cash Burn

Continued negative operating and free cash flow means the business cannot currently fund operations from internally generated cash. The stated dependence on external funding may create dilution or financing pressure and could constrain development if capital becomes harder to secure.

Equity Erosion And Losses

Material equity erosion indicates that accumulated losses have reduced the company’s financial base over time. Without a transition to profitability, further deficits or financing needs could continue diluting shareholder value and limit resources available for commercial execution.

enVVeno Medical News

NVNO FAQ

What was enVVeno Medical’s price range in the past 12 months?
enVVeno Medical lowest stock price was $5.43 and its highest was $14.69 in the past 12 months.
What is enVVeno Medical’s market cap?
enVVeno Medical’s market cap is $3.87M.
When is enVVeno Medical’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were enVVeno Medical’s earnings last quarter?
enVVeno Medical released its earnings results on Oct 30, 2026. The company reported -$6.29 earnings per share for the quarter, missing the consensus estimate of -$3.27 by -$3.02.
Is enVVeno Medical overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does enVVeno Medical pay dividends?
enVVeno Medical does not currently pay dividends.
What is enVVeno Medical’s EPS estimate?
enVVeno Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does enVVeno Medical have?
enVVeno Medical has 694,826 shares outstanding.
What happened to enVVeno Medical’s price movement after its last earnings report?
enVVeno Medical reported an EPS of -$6.29 in its last earnings report, missing expectations of -$3.27. Following the earnings report the stock price went down -4.131%.
Which hedge fund is a major shareholder of enVVeno Medical?
Hedge funds hold enVVeno Medical shares: the largest hedge-fund position in enVVeno Medical is 72,329,173 shares.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology